EUVIMEDEUVIMED entdecken
Crossref

Clinical Advances in Pharmacotherapy for Acute Kawasaki Disease

Fangfang Ma, Hong Liu, Tiantian Han, Wei Han, Fuyong jiao

International Journal of Stem Cells and Medicine · 2026

DOI: 10.58489/2836-5038/023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Stem Cells and Medicine, 2026. Verfasst von Fangfang Ma und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kawasaki disease (KD) is an acute, self-limiting vasculitis that predominantly affects children under 5 years old. The precise etiology and pathogenesis of KD remain incompletely understood. This multisystem disorder represents the most common cause of acquired heart disease in children and may lead to coronary artery lesions (CALs), with severe complications including myocardial infarction and sudden cardiac death. Consequently, standardized treatment during the acute phase is of paramount importance to reduce coronary complications. This article focuses on recent advances in pharmacotherapy for acute-phase KD, aiming to inform clinical management strategies.

Zitieren

APA

Ma, F., Liu, H., Han, T., Han, W., & jiao, F. (2026). Clinical Advances in Pharmacotherapy for Acute Kawasaki Disease. International Journal of Stem Cells and Medicine. https://doi.org/10.58489/2836-5038/023

Vancouver

Ma F, Liu H, Han T, Han W, jiao F. Clinical Advances in Pharmacotherapy for Acute Kawasaki Disease. International Journal of Stem Cells and Medicine. 2026. doi:10.58489/2836-5038/023

BibTeX
@article{Ma2026,
  author = {Ma, Fangfang and Liu, Hong and Han, Tiantian and Han, Wei and jiao, Fuyong},
  title = {Clinical Advances in Pharmacotherapy for Acute Kawasaki Disease},
  journal = {International Journal of Stem Cells and Medicine},
  year = {2026},
  doi = {10.58489/2836-5038/023}
}
Kostenlos starten →